292 related articles for article (PubMed ID: 30585257)
1. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
[TBL] [Abstract][Full Text] [Related]
2. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
[TBL] [Abstract][Full Text] [Related]
6. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Toffoli G; Sharma MR; Marangon E; Posocco B; Gray E; Mai Q; Buonadonna A; Polite BN; Miolo G; Tabaro G; Innocenti F
Clin Cancer Res; 2017 Feb; 23(4):918-924. PubMed ID: 27507617
[No Abstract] [Full Text] [Related]
7. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
8. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Toffoli G; Cecchin E; Gasparini G; D'Andrea M; Azzarello G; Basso U; Mini E; Pessa S; De Mattia E; Lo Re G; Buonadonna A; Nobili S; De Paoli P; Innocenti F
J Clin Oncol; 2010 Feb; 28(5):866-71. PubMed ID: 20038727
[TBL] [Abstract][Full Text] [Related]
9. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Marcuello E; Páez D; Paré L; Salazar J; Sebio A; del Rio E; Baiget M
Br J Cancer; 2011 Jun; 105(1):53-7. PubMed ID: 21654688
[TBL] [Abstract][Full Text] [Related]
10. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G
Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous
Tsai HL; Chen PJ; Chen YC; Li CC; Chang TK; Su WC; Yin TC; Huang CW; Wang JY
J Int Med Res; 2022 Jul; 50(7):3000605221110697. PubMed ID: 35822291
[TBL] [Abstract][Full Text] [Related]
12. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y
Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730
[TBL] [Abstract][Full Text] [Related]
13. High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Manfredi S; Bouché O; Rougier P; Dahan L; Loriot MA; Aparicio T; Etienne PL; Lafargue JP; Lécaille C; Legoux JL; Le Malicot K; Maillard E; Lecomte T; Khemissa F; Breysacher G; Michel P; Mitry E; Bedenne L
Mol Cancer Ther; 2015 Dec; 14(12):2782-8. PubMed ID: 26494856
[TBL] [Abstract][Full Text] [Related]
14. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Yamashita K; Nagashima F; Fujita K; Yamamoto W; Endo H; Miya T; Narabayashi M; Kawara K; Akiyama Y; Ando Y; Ando M; Sasaki Y
Jpn J Clin Oncol; 2011 Feb; 41(2):204-9. PubMed ID: 20965940
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
18. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
[TBL] [Abstract][Full Text] [Related]
19. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
Trials; 2016 Jan; 17():46. PubMed ID: 26811156
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
